

LIST OF TABLES

Table 1	Doses and Duration of Antiviral Drugs According to Viral Genotype	58
Table 2	Modification of Doses of Antiviral Drugs (from Product Labeling Except Where Noted)	65
Table 3	Treatment Milestones and Endpoints	68
Table 4	The patterns of virologic response in treating HCV infection.	76
Table 5	DAA's and HTAs in clinical development at the beginning of 2014	80
Table 6	Approved regimens of sofosbuvir	82
Table 7	Clinical trials of simprevir in genotype 1	84
Table 8	Approved regimens of simprevir in HCV genotype 1	85
Table 9	Direct acting antiviral drugs for HCV infection in clinical development	89
Table10	Therapeutic options likely to be available in 2014-2015.	91
Table11	The overall rates of sustained virologic response of the different currently approved HCV treatment regimens.	92

LIST OF FIGURES

Fig 1	Simplified diagram of the structure of the Hepatitis C virus particle	10
Fig 2	Genome organisation of Hepatitis C virus	11
Fig 3	A simplified diagram of the HCV replication cycle	17
Fig 4	Hepatitis C infection in the United States by source	28
Fig 5	Serologic profile of Hepatitis C infection	32
Fig 6	Prevalence of hepatitis C worldwide in 1999	39
Fig 7	Outcomes of treatment regimens for chronic hepatitis C.	51
Fig 8	Virologic outcomes in patients with chronic HCV-4 receiving PEG-IFN- α plus ribavirin for 24, 36, or 48 weeks.	71